Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone iontophoretic patch
- Development stage
- Unknown
- Lead developer
- Travanti Pharma
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
The dexamethasone iontophoretic patch, specifically the version developed by Travanti Pharma (code name TPI-927), is a drug-device combination designed for the localized treatment of inflammatory conditions like lateral epicondylitis. The system consists of a wearable, self-contained patch that utilizes iontophoresis—a technique using a low-level electrical current—to drive dexamethasone sodium phosphate through the skin and into the underlying tissues. Dexamethasone is a potent synthetic glucocorticoid that binds to and activates the glucocorticoid receptor, leading to the suppression of inflammatory mediators and the reduction of pain and swelling. This delivery method aims to provide high local concentrations of the steroid while minimizing the systemic side effects typically associated with oral or injectable corticosteroids. Travanti Pharma conducted Phase 2 clinical trials for this indication before being acquired by Teikoku Pharma USA.
- Brand names
- IontoPatch
- Other names
- dexamethasone sodium phosphate iontophoretic patchTravanti Dexamethasone Iontophoretic Patch
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone iontophoretic patch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone iontophoretic patch.